Co-Diagnostics anticipates filing FDA 510(k) in the third quarter as CoSara expands TAM to approximately $13B
Source: SeekingAlpha
2026-05-14 19:12:14 ET
More on Co-Diagnostics
- Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
- Co-Diagnostics GAAP EPS of -$4.06 misses by $0.31, revenue of $0.15M misses by $0.01M
- Co-Diagnostics JV secures KSA facility lease deal; CODX rallies 16% premarket
- Seeking Alpha’s Quant Rating on Co-Diagnostics
Read the full article on Seeking Alpha
For further details see:
Co-Diagnostics anticipates filing FDA 510(k) in the third quarter as CoSara expands TAM to approximately $13B
Co-Diagnostics Inc.
NASDAQ: CODX
CODX Trading
46.03% G/L:
$2.015 Last:
98,317,390 Volume:
$1.95 Open:
CODX Latest News
May 19, 2026 09:00:00 am
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak AlertCODX Stock Data
$4,902,373
1,981,899
N/A
2
2252057%
Medical Equipment & Supplies
Healthcare
US
Salt Lake City
